Commentary: Shared decision making for weight-lowering medications in China

References

[1] Li J, Shi Q, Gao Q, et al. Obesity pandemic in China: epidemiology, burden, challenges, and opportunities. Chin Med J (Engl). 2022;135(11):1328-1330.

[2] Wu NW, Lyu XF, An ZM, Li SY. Adiposity in Chinese people with type 1 diabetes. World J Diabetes. 2024;15(7):1404-1408.

[3] Jastreboff AM, Kushner RF. New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics. Annu Rev Med. 2023;74:125-139.

[4] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.

[5] Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. Bmj. 2023;381:e074068.

[6] Liu D, Li N, Zhou Y, et al. Sex-specific associations between skeletal muscle mass and incident diabetes: a population-based cohort study. Diabetes Obes Metab. 2024;26(3):820-828.

[7] Endocrinology CSO. Guideline for chronic weight management and clinical practice of anti-obesity medicine(2024). Chin J Endocrinol Metab. 2024;40(7).

[8] Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. Bmj. 2021;373:n1091.

[9] Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024;403(10434):e21-e31.

[10] Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.